Pulmonary hypertension (PH) is a complex and often misdiagnosed condition that requires a comprehensive understanding for effective management. This article aims to provide an in-depth guide to PH, focusing on its pathophysiology, diagnosis, and treatment strategies.
PH is characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, leading to right ventricular failure. It is classified into five groups based on etiology: pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung diseases and/or hypoxia, chronic thromboembolic PH, and PH with unclear multifactorial mechanisms.
Diagnosis of PH is a multi-step process involving clinical assessment, echocardiography, and right heart catheterization. Echocardiography serves as an initial screening tool, while right heart catheterization confirms the diagnosis by directly measuring pulmonary pressures. Other diagnostic investigations include lung function tests, chest radiography, and computed tomography (CT) scan to identify underlying causes.
Treatment of PH is tailored according to its etiology and severity. General measures include lifestyle modifications, oxygen therapy, and anticoagulation. Specific treatment for PAH includes endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs. In severe cases, lung transplantation may be considered.
Healthcare professionals play a crucial role in the early detection and management of PH. A high index of suspicion is required in patients presenting with unexplained dyspnea. Multidisciplinary approach involving cardiologists, pulmonologists, radiologists, and pathologists is often required for optimal patient care.
PH is a complex disease requiring a comprehensive understanding for effective management. Early diagnosis and appropriate treatment can significantly improve patient outcomes. Continuous education and collaboration among healthcare professionals are essential in achieving this goal.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation